X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (155) 155
humans (143) 143
male (112) 112
female (109) 109
glycated hemoglobin a - metabolism (104) 104
middle aged (74) 74
adult (71) 71
blood glucose - metabolism (69) 69
aged (50) 50
diabetes (48) 48
glycated hemoglobin a - analysis (45) 45
glucose (41) 41
diabetes mellitus, type 2 - blood (39) 39
diabetes mellitus (35) 35
glycosylated hemoglobin (32) 32
endocrinology & metabolism (29) 29
diabetes mellitus, type 1 - blood (26) 26
insulin (26) 26
mellitus (26) 26
animals (25) 25
metabolism (25) 25
risk factors (25) 25
glucose metabolism (24) 24
hypoglycemic agents - therapeutic use (23) 23
insulin - blood (23) 23
adolescent (22) 22
glucose tolerance test (22) 22
hemoglobin (22) 22
medicine, general & internal (21) 21
prevalence (21) 21
blood glucose - analysis (20) 20
type 2 diabetes (20) 20
insulin resistance (19) 19
insulin-resistance (19) 19
insulin - therapeutic use (18) 18
physiological aspects (18) 18
rats (18) 18
diabetes mellitus, type 2 - drug therapy (17) 17
body mass index (16) 16
hemoglobin a, glycosylated, metabolism (16) 16
hemoglobin a; glycosylated/metabolism (16) 16
risk (16) 16
blood glucose/metabolism (15) 15
hemoglobin a (15) 15
research (15) 15
0 (14) 14
abridged index medicus (14) 14
dextrose (14) 14
hemoglobin a, glycosylated/me [metabolism] (14) 14
obesity (14) 14
pharmacology & pharmacy (14) 14
treatment outcome (14) 14
blood (13) 13
child (13) 13
fasting (13) 13
glucose - metabolism (13) 13
glycemic control (13) 13
hyperglycemia (13) 13
mortality (13) 13
time factors (13) 13
aged, 80 and over (12) 12
diabetes mellitus - blood (12) 12
diabetes mellitus, experimental - drug therapy (12) 12
diabetes mellitus, type 2 - metabolism (12) 12
diabetes mellitus, type 2 - therapy (12) 12
internal medicine (12) 12
medical and health sciences (12) 12
medicin och hälsovetenskap (12) 12
diabetes mellitus, type 1 - drug therapy (11) 11
diabetes mellitus, type 2 - complications (11) 11
glycated hemoglobin a (11) 11
pregnancy (11) 11
analysis (10) 10
article (10) 10
cholesterol - blood (10) 10
follow-up studies (10) 10
rats, wistar (10) 10
triglycerides - blood (10) 10
association (9) 9
blood glucose, metabolism (9) 9
blood glucose/me [metabolism] (9) 9
carbohydrate metabolism (9) 9
care and treatment (9) 9
complications (9) 9
diabetes mellitus, type 2 - epidemiology (9) 9
endocrine system diseases (9) 9
glycosylated/metabolism (9) 9
hemoglobin a, glycosylated [metabolism] (9) 9
hypoglycemic agents - pharmacology (9) 9
insulin - metabolism (9) 9
liver - drug effects (9) 9
management (9) 9
medical research (9) 9
mice (9) 9
randomized controlled trials as topic (9) 9
studies (9) 9
therapy (9) 9
biomarkers - blood (8) 8
blood glucose - drug effects (8) 8
body weight (8) 8
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (157) 157
Russian (8) 8
Chinese (7) 7
French (3) 3
German (3) 3
Italian (3) 3
Hungarian (2) 2
Japanese (2) 2
Korean (2) 2
Polish (2) 2
Spanish (2) 2
Czech (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation: Heart Failure, ISSN 1941-3289, 01/2016, Volume 9, Issue 1
Background The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We... 
heart failure | Clinical trial | diabetes mellitus | prognosis | treatment outcome | clinical trial | CARDIAC & CARDIOVASCULAR SYSTEMS | PREDICTOR | TOLERANCE | HEMOGLOBIN A(1C) | HOSPITALIZATION | INHIBITION | A1C | INSULIN-RESISTANCE | GLUCOSE | DYSFUNCTION | OUTCOMES | Diabetes Mellitus - blood | Single-Blind Method | Prevalence | Prospective Studies | Ventricular Function, Left | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Heart Failure - diagnosis | Diabetes Mellitus - diagnosis | Diabetes Mellitus - mortality | Prediabetic State - epidemiology | Heart Failure - mortality | Prediabetic State - blood | Risk Assessment | Comorbidity | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Biomarkers - blood | Heart Failure - drug therapy | Prediabetic State - mortality | Prediabetic State - diagnosis | Stroke Volume | Disease-Free Survival | Diabetes Mellitus - epidemiology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Blood Glucose - metabolism | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | Index Medicus | 10093 | 10150 | 10094 | Original | glucose | hospitalization | inhibition | Klinisk medicin | dysfunction | Clinical Medicine | a1c | insulin-resistance | hemoglobin a(1c) | Cardiovascular System & Cardiology | predictor | cardiovascular risk | tolerance
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 05/2004, Volume 89, Issue 5, pp. 2078 - 2084
Journal Article
Cell Metabolism, ISSN 1550-4131, 11/2012, Volume 16, Issue 5, pp. 625 - 633
Journal Article
The Lancet, ISSN 0140-6736, 06/2002, Volume 359, Issue 9324, pp. 2140 - 2144
Glycometabolic state at hospital admission is an important risk marker for long-term mortality in patients with acute myocardial infarction, whether or not... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | ADMISSION | INSULIN-TREATMENT | PROGNOSIS | TOLERANCE | RISK | INFUSION | TERM | CORONARY-HEART-DISEASE | STRESS HYPERGLYCEMIA | Body Mass Index | Glucose Tolerance Test | Prevalence | Prospective Studies | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Myocardial Infarction - metabolism | Sweden - epidemiology | Diabetes Mellitus, Type 2 - epidemiology | Diabetes Mellitus, Type 2 - diagnosis | Glucose - metabolism | Female | ROC Curve | Hemodynamics | Measurement | Physiological aspects | Glucose metabolism | Glucose intolerance | Glucose tolerance tests | Heart attack | Cardiovascular disease | Heart attacks | Glucose | Diabetes | Metabolism | Medical screening | Myocardial infarction | Laboratories | Identification methods | Family medical history | Blood | Hyperglycemia | Diagnosis | Cardiology | Heart failure | Hypertension | Fasting | Risk groups | Abnormalities | Diabetes mellitus | Angina pectoris | Patients | Discharge | Blood levels | Disease prevention | Glucose tolerance | Infarction | Index Medicus | Abridged Index Medicus | Hemoglobin A; Glycosylated/metabolism | Myocardial Infarction/metabolism | Diabetes Mellitus; Type 2/diagnosis/epidemiology | Glucose/metabolism | Research Support; Non-U.S. Gov't | Hemodynamic Processes | Sweden/epidemiology
Journal Article
Journal Article
PLoS Medicine, ISSN 1549-1277, 08/2008, Volume 5, Issue 8, pp. 1278 - 1286
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 10/2005, Volume 90, Issue 10, pp. 5684 - 5691
Context: In clinical practice, patients with acromegaly may be switched from therapy with long-acting somatostatin analogs to pegvisomant. The effect of... 
MORTALITY | RISK-FACTORS | GROWTH-HORMONE | DOSE-RESPONSE | MORBIDITY | TOLERANCE | ENDOCRINOLOGY & METABOLISM | RESISTANCE | HORMONE-RECEPTOR ANTAGONIST | INSULIN SENSITIVITY | FEATURES | Area Under Curve | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Insulin - blood | Human Growth Hormone - analogs & derivatives | Pituitary Neoplasms - complications | Acromegaly - etiology | Human Growth Hormone - therapeutic use | Adenoma - complications | Adult | Female | Human Growth Hormone - administration & dosage | Homeostasis - drug effects | Octreotide - administration & dosage | Acromegaly - blood | Glucose Tolerance Test | Octreotide - adverse effects | Human Growth Hormone - adverse effects | Octreotide - therapeutic use | Acromegaly - drug therapy | Adolescent | Adenoma - pathology | Glucose - metabolism | Human Growth Hormone - blood | Blood Glucose - metabolism | Delayed-Action Preparations | Insulin-Like Growth Factor I - metabolism | Index Medicus | Abridged Index Medicus | Human Growth Hormone/administration & dosage/adverse effects/analogs & derivatives/blood/therapeutic use | Adenoma/complications/pathology | Blood Glucose/metabolism | Insulin/blood | Hemoglobin A; Glycosylated/metabolism | Homeostasis/drug effects | Insulin-Like Growth Factor I/metabolism | Pituitary Neoplasms/complications | Acromegaly/blood/drug therapy/etiology | Octreotide/administration & dosage/adverse effects/therapeutic use | Glucose/metabolism
Journal Article
Diabetes Care, ISSN 0149-5992, 2009, Volume 32, Issue 5, pp. 762 - 768
0.0001). beta-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment... 
NON-INFERIORITY | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | BASAL INSULIN | GLUCOSE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | TWICE-DAILY EXENATIDE | Metformin - therapeutic use | C-Peptide - blood | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Exenatide | Female | Insulin - analogs & derivatives | Insulin Secretion | Body Mass Index | Hypoglycemic Agents - therapeutic use | Insulin-Secreting Cells - physiology | Insulin, Long-Acting | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Insulin Glargine | Arginine - pharmacology | Venoms - therapeutic use | Kinetics | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Peptides - therapeutic use | Index Medicus | Original Research | Hemoglobin A | Insulin/analogs & derivatives/secretion/therapeutic use | Blood Glucose/metabolism | Type 2/blood/drug therapy/physiopathology | MEDICIN OCH HÄLSOVETENSKAP | Diabetes Mellitus | Insulin-Secreting Cells/drug effects/physiology | Venoms/therapeutic use | Metformin/therapeutic use | Glycosylated/metabolism | Peptides/therapeutic use | Arginine/pharmacology | Hypoglycemic Agents/therapeutic use | C-Peptide/blood | MEDICAL AND HEALTH SCIENCES
Journal Article
Diabetes Care, ISSN 0149-5992, 04/2004, Volume 27, Issue 4, pp. 955 - 962
Journal Article
Diabetes Care, ISSN 0149-5992, 10/2003, Volume 26, Issue 10, pp. 2770 - 2776
Journal Article